Amphastar Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 1, 2026, details the results of the Annual Meeting of Stockholders held by Amphastar Pharmaceuticals, Inc. The filing covers the voting outcomes for director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following material outcomes were reported from the Annual Meeting:
- Election of Directors: Three Class I directors were elected to serve until the 2029 annual meeting.
- David Gaugh: Elected with 35,242,863 votes For vs. 209,084 Against.
- William J. Peters: Elected with 23,652,131 votes For vs. 11,785,772 Against.
- Jacob Liawatidewi: Elected with 23,224,791 votes For vs. 12,212,988 Against.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (39,179,786 For vs. 684,828 Against).
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on an advisory basis (32,585,908 For vs. 2,779,281 Against).
- Frequency of Say-on-Pay Votes: Stockholders voted to hold future advisory votes on executive compensation annually (33,816,071 votes for 1 Year). The next frequency vote is required no later than the 2032 annual meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the full slate of director nominees and the specific reasons for the significant "Against" votes received by William J. Peters and Jacob Liawatidewi (approximately 33% and 34% of votes cast, respectively).
- Confirm the company's commitment to annual Say-on-Pay votes as mandated by the shareholder advisory result.
- Review the definitive proxy statement filed on April 13, 2026, for detailed background on the director nominees and executive compensation packages.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.